Cannabigerol (CBG) Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 112 studies associated with Cannabigerol (CBG).
Here is a small sampling of Cannabigerol (CBG) studies by title:
- In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties
- Will Cannabigerol Trigger Neuroregeneration after a Spinal Cord Injury? An In Vitro Answer from NSC-34 Scratch-Injured Cells Transcriptome
- Cannabinoids: Therapeutic Use in Clinical Practice
- Geospatiotemporal and causal inference study of cannabis and other drugs as risk factors for female breast cancer USA 2003–2017
- Fetal Exposure to Cannabis and Childhood Metabolic Outcomes: The Healthy Start Study
Components of the Cannabigerol (CBG) Research Dashboard
- Top medical conditions associated with Cannabigerol (CBG)
- Proven effects in clinical trials for Cannabigerol (CBG)
- Receptors associated with Cannabigerol (CBG)
- Individual study details for Cannabigerol (CBG)
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Organ Systems
- Study Result
- Year of Publication
Overview - Cannabigerol (CBG)
Description of Cannabigerol (CBG)
The plant-based (phytocannabinoid) CBG was discovered in 1964 (CBG-C5). In its acid form CBG is the parent molecule from which all other plant-based cannabinoids are metabolized.
Geranylolivetol (plus numerous others)
IUPAC Name: 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentylbenzene-1,3-diol
Molecular Formula: C21H32O2
Cannabigerol (CBG) Properties and Effects
• Muscle relaxant
• May be anti-proliferative in cases of prostate and colorectal cancer
• Antibacterial (MRSA)
• Appetite stimulant (in cases of anorexia, cachexia)
• Anti-parasitical (leishmania)
• Pre-clinical trials suggest potential benefits in treating neurological disorders such as Huntington's Disease.
Cannabigerol (CBG) Receptor Binding
Endocannabinoid system (ECS)
• Agonist at CB1 (Ki 440nM see Pertwee et al. 2008)
• Agonist at CB2 (Ki 337nM see Pertwee et al. 2008)
• TRPV1 (significant agonist)
• TRPA1 (significant agonist)
• TRPM8 [inhibitor (antagonist)]
• 5HT1A serotonin receptors (moderate inhibitor)
• Alpha-2-andrenergic-receptor sites (agonist)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.